Last reviewed · How we verify

Herpes labialis — Treatment Landscape & Competitive Intelligence

Herpes labialis (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Herpes labialis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Denavir PENCICLOVIR Mylan Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] 1996-01-01
Valtrex valaciclovir GSK Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor 1995-01-01
Zovirax ACYCLOVIR Ligand Pharms Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC] Purine nucleoside phosphorylase 1982-01-01
Abreva Abreva University of Utah Envelope glycoprotein
Aciclovir Aciclovir Assistance Publique Hopitaux De Marseille Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase
ACYC ACYC Ligand Pharms Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Ligand Pharms · 2 drugs in Herpes labialis
  2. · 1 drug in Herpes labialis
  3. Assistance Publique Hopitaux De Marseille · 1 drug in Herpes labialis
  4. GSK · 1 drug in Herpes labialis
  5. Mylan · 1 drug in Herpes labialis
  6. University of Utah · 1 drug in Herpes labialis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Herpes labialis:

Cite this brief

Drug Landscape (2026). Herpes labialis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/herpes-labialis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing